JAGUAR HEALTH, INC. Proceeds from Issuance of Warrants
JAGUAR HEALTH, INC. (JAGX) reported Proceeds from Issuance of Warrants of $154.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfWarrants · last filed 2026-08-19
- JAGUAR HEALTH, INC. proceeds from issuance of warrants for the quarter ending 2023-12-31 was $1.00K.
- JAGUAR HEALTH, INC. proceeds from issuance of warrants for the quarter ending 2023-09-30 was $0.00.
- JAGUAR HEALTH, INC. proceeds from issuance of warrants for fiscal 2023 was $1.24M.
| Period end | Proceeds from Issuance of Warrants | Proceeds from Issuance of Warrants 3 month | Proceeds from Issuance of Warrants 6 month | Proceeds from Issuance of Warrants 9 month | Proceeds from Issuance of Warrants 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $154.00K 10-Q · filed 2026-08-19 | ||||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-13 | ||||
| 2023-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.00K derived: sum of 2 quarters · filed 2025-03-31 | $1.24M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $1.24M 10-Q · filed 2024-11-13 | |||
| 2023-06-30 | $1.24M 10-Q · filed 2024-08-13 | ||||
| 2020-03-23 | $653.00K 10-Q · filed 2021-11-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |